Entera Bio (ENTX) Cash from Investing Activities (2021 - 2025)
Entera Bio (ENTX) posted quarterly Cash from Investing Activities of -$27000.0 for Q4 2025, down 800.0% year-on-year from $3857.1 in Q4 2024, and up 37.21% on a QoQ basis from -$43000.0 in Q3 2025.
Entera Bio (ENTX) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Entera Bio (ENTX) has reported Cash from Investing Activities for 5 consecutive years, with -$27000.0 the latest figure, recorded in Q4 2025.
- Quarterly Cash from Investing Activities fell 800.0% year-over-year to -$27000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$99000.0 (down 800.0% YoY) and the FY2025 annual result came in at -$107000.0, down 3466.67% from the prior year.
- Cash from Investing Activities improved to -$27000.0 in Q4 2025 per ENTX's latest filing, from -$43000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for ENTX reached as high as -$1000.0 in Q2 2023 and fell as low as -$57000.0 in Q3 2022.
- A 5-year average of -$17571.4 and a median of -$10500.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 94.74% — and 2025, when it tumbled 800.0%.
- Year by year, Cash from Investing Activities stood at -$10000.0 in 2021, then surged by 70.0% to -$3000.0 in 2022, then tumbled by 66.67% to -$5000.0 in 2023, then jumped by 40.0% to -$3000.0 in 2024, then slumped by 800.0% to -$27000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$27000.0, -$43000.0, and -$29000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27,000.00 |
| Dec 31, 2025 | -27,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Sep 30, 2022 | -57,000.00 |